GlassScriptPhysician profile
Colleen Tetzlaff
NPI 1144306689
$1,741.96
in general payments reported to CMS, 2019-2025
15 companies · $489 in 2025
The $489 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $36.16 · 2022: $45.59 · 2023: $341 · 2024: $830 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,060 · Honoraria: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,060.21 |
| Honoraria | $600.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $734.95 | 2023-2025 | |
| Exelixis INC. | $169.84 | 2024-2025 | Cabometyx |
| Merck Sharp & Dohme LLC | $145.96 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Janssen Biotech, INC. | $123.93 | 2023-2025 | Erleada |
| Gilead Sciences, INC. | $99.24 | 2023 | Trodelvy |
| Novartis Pharmaceuticals Corporation | $88.64 | 2022-2025 | |
| Stemline Therapeutics INC. | $83.20 | 2023 | Orserdu |
| Astellas Pharma Global Development | $61.87 | 2023 | Xtandi |
| Daiichi Sankyo INC. | $47.87 | 2025 | Vanflyta |
| Astrazeneca Pharmaceuticals LP | $46.74 | 2024-2025 | Enhertu, Calquence |
| Bayer Healthcare Pharmaceuticals INC. | $39.30 | 2024 | |
| Myovant Sciences INC. | $36.16 | 2021 | |
| Sumitomo Pharma America, INC. | $28.87 | 2024 | Orgovyx |
| Eisai INC. | $19.67 | 2023 | |
| Morphosys, US INC. | $15.72 | 2023 | Monjuvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colleen Tetzlaff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.